A Quantitative Enzyme Immunoassay for Primary Fibrinogenolysis Products in Plasma

 

PDF Download Buy Article Permissions and Reprints

Summary

We have developed a two-step enzyme immunoassay (EIA) that allows the quantitation of degradation products derived from fibrinogen (FbgDP) and that does not detect degradation products derived from cross-finked (XDP) or noncrosslinked fibrin (fdp).

The EIA is based on two monoclonal antibodies (FDP-14 and Y-18), developed in our institute. FDP-14 is used as catching antibody. It complexes exclusively with degradation products, irrespective whether these are derived from fibrinogen or from fibrin. It does not complex with intact fibrinogen or fibrin. Y-18 is reactive with fibrinogen and fibrinopeptide A-comprising fibrinogen fragments. It is used, conjugated with horse-radish peroxy-dase, as tagging antibody.

The FbgDP-EIA is highly specific, accurate and sensitive. The coefficient of variation is between 3 and 8%; the lower detection limit is less than 0.025 μg/ml.

The assay has been applied to plasma from patients with suspected disseminated intravascular coagulation (DIC), to plasma from patients undergoing streptokinase (SK) therapy for acute myocardial infarction and to plasma from newborn babies.

DIC patients had no or very low levels of FbgDP, but high levels of other degradation products, SK-treated patients showed high levels of degradation products two hours after termination of the SK infusion. A considerable fraction of these degradation products was shown to be FbgDP. Plasma from newborn babies contained elevated levels of FbgDP associated with prolonged prothrombin times.

• References

• 1 Sterrenberg L, Haak HL, Brommer E JP, Nieuwenhuizen W. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 1985; 15: 126-133
  PubMedGoogle Scholar
• 2 Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983; 31: 767-778
  CrossrefPubMedGoogle Scholar
• 3 Haverkate F, Koopman J, Koppert P, Nieuwenhuizen W. Determination of fibrin(ogen) degradation products (FDP) in plasma, using a monoclonal antibody. Scand J Clin Lab Invest 1985; 45 suppl. (178) 153
  PubMedGoogle Scholar
• 4 Koppert PW, Huijsmans C MG, Haverkate F, Engbers J, Brommer E JP, Nieuwenhuizen W. A monoclonal antibody, specific for human fibrinogen and fibrinopeptide A-containing fragments. Its application in an enzyme immunoassay for fibrinogen degradation products, suitable for use in plasma. In Fibrinogen, fibrin formation and fibrinolysis. Lane DA, Jasani K, Scully MF, Henschen A. (Eds). Walter de Gruyter; Berlin: 1986: 279-295
  Google Scholar
• 5 Koopman J, Haverkate F, Koppert PW, Nieuwenhuizen W, Brommer E JP, Van der Werf W GC. A new enzyme immunoassay of fibrin(ogen) degradation products in plasma using a monoclonal antibody. In Fibrinogen, fibrin formation and fibrinolysis. Lane DA, Jasani K, Scully MF, Henschen A. (Eds). Walter de Gruyter; Berlin: 1986: 261-270
  Google Scholar
• 6 Koppert PW, Koopman J, Haverkate F, Nieuwenhuizen W. Production and characterization of a monoclonal antibody, reactive with a specific neoantigenic determinant (comprising Bβ 54-118) in degradation products of fibrin and of fibrinogen. Blood 1986; 68: 437-441
  PubMedGoogle Scholar
• 7 Koppert PW, Huijsmans C MG, Nieuwenhuizen W. A monoclonal antibody, specific for human fibrinogen, fibrinopeptide A-containing fragments and not reacting with free fibrinopeptide A. Blood 1985; 66: 503-507
  PubMedGoogle Scholar
• 8 Nieuwenhuizen W, Voskuilen M, Hermans J. Anticoagulant and calcium-binding properties of high-molecular weight derivatives of human fibrinogen (plasmin fragments Y). Biochim Biophys Acta 1982; 708: 313-316
  CrossrefPubMedGoogle Scholar
• 9 Koopman J, Haverkate F. Formation of fibrin degradation products from a non-anticoagulated whole blood clot. In Fibrinogen, structure, functional aspects, metabolism. Haverkate F, Henschen A, Nieuwenhuizen W, Straub PW. (Eds). Walter de Gruyter; Berlin: 1983: 255-260
  Google Scholar
• 10 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgGl, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immunochem 1978; 15: 429-436
  CrossrefPubMedGoogle Scholar
• 11 Bouvet JP, Pires R, Pillot J. A modified gel filtration technique producing an unusual exclusion volume of IgM: a simple way of preparing monoclonal IgM. J Immunol Meth 1984; 66: 299-305
  CrossrefPubMedGoogle Scholar
• 12 Carlsson J, Drevin H, Axen R. Protein thiolation and -reversible protein-protein conjugation. N-succinimidyl 3-(2-pyridyldithio) propionate: a new heterobifunctional reagent. Biochem J 1978; 173: 723-737
  CrossrefPubMedGoogle Scholar
• 13 Bos ES, Van der Doelen AA, Van Rooy N, Schuurs A HW M. 3,3’, 5,5’-Tetramethyl benzidine as an Ames test negative chromogen for horse-radish peroxidase in enzyme immunoassay. J Immunoassay 1981; 2: 187-204
  PubMedGoogle Scholar
• 14 Hamulyak K, Devilée PP, Nieuwenhuizen W, Hemker HC. Fibrin(ogen) degradation products in newborn plasmas can cause a false interpretation of the prolongation of the thrombotest clotting time. In Aspects of the haemostatic mechanisms in newborns. Thesis K. Hamulyak, Maastricht; The Netherlands: 1985: 51-64
  Google Scholar